MiBo ThermoFlo Lid Temperature Evaluation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 4
- Locations
- 2
- Primary Endpoint
- Posterior Eyelid Temperature (Palpebral Conjunctiva)
Study Overview
Brief Summary
This study is a prospective, contralateral, single-site, single-visit unmasked evaluation of external and internal eyelid temperature after treatment with the MiBo ThermoFlo.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Potential subjects must satisfy all the following criteria to be enrolled in the study:
- •The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- •Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- •Between 18 and 80 (inclusive) years of age at the time of screening.
- •Subjects must possess a functional/usable pair of spectacles and bring them to the visit (only if applicable - to the investigators discretion).
Exclusion Criteria
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Currently pregnant or breastfeeding.
- •Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with participation in the study.
- •Clinically significant (Grade 3 or 4 on the FDA classification scale) slit lamp findings (e.g. corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection).
- •Grade 3-4 Percentage of Partial Meibomian Glands on the Pult 5-point grading scale.
- •Any active Ocular Infection or Inflammation
- •Any history of eyelid surgery or abnormality
- •History of Metal Implants in the Eyelids
- •Any known hypersensitivity or allergic reaction to ultrasound coupling gel.
- •LASIK Surgery within 2 weeks of the Baseline Visit.
- •Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
- •History of MiBo ThermoFlo or Lipiflow treatment Within the Last 6 months.
- •Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
Outcomes
Primary Outcomes
Posterior Eyelid Temperature (Palpebral Conjunctiva)
Time Frame: 12-minutes post treatment
Ocular surface temperature is usually 34.03±0.51ºC in the normal eye. The temperature required to melt obstructive secretions in the Meibomian glands ranges from 32- 35°C but the more severely obstructed glands present in MGD could require a temperature of \>40°C, for effective treatment. there is an approximate 5°C difference in temperature between heat applied on the external eyelid surfaces and that reaches the inner surface of the lids, where the meibomian glands are located. This difference was due to both dissipation of heat while passing through the lid tissues and to constant movement of blood through vasculature wicking heat away from the lids. Therefore, achieving the desired temperature of 40°C at the palpebral conjunctiva requires a constant heat of at least 45°C be maintained on the outer lid surface, a temperature which could be both uncomfortable and risk causing thermal injury to the eyelid skin.
Secondary Outcomes
No secondary outcomes reported